[Therapeutic agents for disorders of bone and calcium metabolism: ED-71].
ED-71 is a new vitamin D receptor ligand, bearing a hydroxypropoxy substituent at the 2beta-position of 1alpha, 25 (OH) (2)D(3). In ovariectomized rats, ED-71 increased lumbar vertebral bone mass and bone strength by inhibiting bone resorption and maintaining bone formation without causing hypercalcemia. In a randomized, placebo-controlled, double-blinded clinical trial for osteoporotic subjects with sufficient vitamin D supply, ED-71 treatment for 12 months can effectively increase lumbar and hip bone mineral density in a dose-dependent manner without causing sustained hypercalcemia. Serum calcium (Ca) and urinary Ca excretion was increased dose-dependently by ED-71 treatment, but it was in normal range. These results demonstrate that ED-71 can effectively increase bone mass without causing hypercalcemia, and suggest that ED-71 can be a promising candidate for the treatment of osteoporosis.
Tsuji
Naoki
N
Chugai Pharmaceutical Co., Ltd, Clinial Research 2nd Dept.
Takahashi
Fumiaki
F
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D014807:Vitamin D / Q000031:analogs & derivatives
D014807:Vitamin D; D002117:Calcitriol; C547512:eldecalcitol; D002118:Calcium